神経膠腫治療薬の世界市場2019-2023

◆英語タイトル:Global Glioma Therapeutics Market 2019-2023
◆商品コード:IRTNTR30499
◆発行会社(リサーチ会社):Technavio
◆発行日:2018年12月14日
◆ページ数:114
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥321,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、神経膠腫治療薬の世界市場について調査・分析し、市場概要、市場環境、神経膠腫治療薬市場規模、製品別(小分子、生物製剤)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・神経膠腫治療薬の世界市場概要
・神経膠腫治療薬の世界市場環境
・神経膠腫治療薬の世界市場動向
・神経膠腫治療薬の世界市場規模
・神経膠腫治療薬の世界市場:業界構造分析
・神経膠腫治療薬の世界市場:製品別(小分子、生物製剤)
・神経膠腫治療薬の世界市場:地域別市場規模・分析
・神経膠腫治療薬の北米市場規模・予測
・神経膠腫治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・神経膠腫治療薬のアジア太平洋市場規模・予測
・神経膠腫治療薬の主要国分析
・神経膠腫治療薬の世界市場:意思決定フレームワーク
・神経膠腫治療薬の世界市場:成長要因、課題
・神経膠腫治療薬の世界市場:競争環境
・神経膠腫治療薬の世界市場:関連企業情報(ベンダー分析)

主な分析対象企業は、F. Hoffmann-La Roche、Merck Sharp & Dohme、Mylan、NextSource Biotechnology、Novartisなどです。
【レポートの概要】

About this market
Strategic alliances to drive growth in the market. Pharmaceutical companies are collaborating to develop medications for the treatment of glioma. These alliances can enhance R&D activities for new drugs for the treatment of glioma. Technavio’ s analysts have predicted that the glioma therapeutics market will register a CAGR of more than 9% by 2023.
Market Overview
Expected approval of late-stage pipeline molecules
As the market is currently experiencing an acute lack of approved therapies, these late-stage pipeline molecules can tap into this unmet demand from the glioma patient pool. Once these molecules are launched during the forecast period, the global glioma therapeutics market should observe strong value growth from these newly launched therapeutics.
Availability of alternative therapies
Despite the availability of medications for the treatment of the glioma, there are several alternative procedures. The high cost, side effects, and long duration of treatment with the available medications are increasing patients’ inclination toward the surgical and radiation treatment options.
For the detailed list of factors that will drive and challenge the growth of the glioma therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including NextSource Biotechnology and Novartis the competitive environment is quite intense. Factors such as the expected approval of late-stage pipeline molecules and the strategic alliances, will provide considerable growth opportunities to glioma therapeutics manufactures. F. Hoffmann-La Roche, Merck Sharp & Dohme, Mylan, NextSource Biotechnology, and Novartis are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY PRODUCT
• Market segmentation by product
• Comparison by product
• Small molecules – Market size and forecast 2018-2023
• Biologics – Market size and forecast 2018-2023
• Market opportunity by product
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• Americas – Market size and forecast 2018-2023
• EMEA – Market size and forecast 2018-2023
• APAC – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• F. Hoffmann-La Roche
• Merck Sharp & Dohme
• Mylan
• NextSource Biotechnology
• Novartis
PART 13: APPENDIX
• Research methodology
• List of abbreviations


Exhibit 01: Years in consideration
Exhibit 02: Global oncology therapeutics market
Exhibit 03: Segments of global oncology therapeutics market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Product – Market share 2018-2023 (%)
Exhibit 19: Comparison by product
Exhibit 20: Small molecules – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Small molecules – Year-over-year growth 2019-2023 (%)
Exhibit 22: Biologics – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Biologics – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by product
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in Americas
Exhibit 31: EMEA – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: EMEA – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in EMEA
Exhibit 34: APAC – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: APAC – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in APAC
Exhibit 37: Key leading countries
Exhibit 38: Market opportunity
Exhibit 39: Decision framework
Exhibit 40: Some of the therapeutics that received orphan drug designation from the US FDA are mentioned below
Exhibit 41: Impact of drivers and challenges
Exhibit 42: Vendor landscape
Exhibit 43: Landscape disruption
Exhibit 44: Vendors covered
Exhibit 45: Vendor classification
Exhibit 46: Market positioning of vendors
Exhibit 47: F. Hoffmann-La Roche – Vendor overview
Exhibit 48: F. Hoffmann-La Roche – Business segments
Exhibit 49: F. Hoffmann-La Roche – Organizational developments
Exhibit 50: F. Hoffmann-La Roche – Geographic focus
Exhibit 51: F. Hoffmann-La Roche – Segment focus
Exhibit 52: F. Hoffmann-La Roche – Key offerings
Exhibit 53: F. Hoffmann-La Roche – Key customers
Exhibit 54: Merck Sharp & Dohme – Vendor overview
Exhibit 55: Merck Sharp & Dohme – Business segments
Exhibit 56: Merck Sharp & Dohme – Organizational developments
Exhibit 57: Merck Sharp & Dohme – Geographic focus
Exhibit 58: Merck Sharp & Dohme – Segment focus
Exhibit 59: Merck Sharp & Dohme – Key offerings
Exhibit 60: Merck Sharp & Dohme – Key customers
Exhibit 61: Mylan – Vendor overview
Exhibit 62: Mylan – Business segments
Exhibit 63: Mylan – Organizational developments
Exhibit 64: Mylan – Geographic focus
Exhibit 65: Mylan – Key offerings
Exhibit 66: Mylan – Key customers
Exhibit 67: NextSource Biotechnology – Vendor overview
Exhibit 68: NextSource Biotechnology – Organizational developments
Exhibit 69: NextSource Biotechnology – Key offerings
Exhibit 70: NextSource Biotechnology – Key customers
Exhibit 71: Novartis – Vendor overview
Exhibit 72: Novartis – Business segments
Exhibit 73: Novartis – Organizational developments
Exhibit 74: Novartis – Geographic focus
Exhibit 75: Novartis – Segment focus
Exhibit 76: Novartis – Key offerings
Exhibit 77: Novartis – Key customers
Exhibit 78: Validation techniques employed for market sizing
Exhibit 79: List of abbreviations



【掲載企業】

F. Hoffmann-La Roche、Merck Sharp & Dohme、Mylan、NextSource Biotechnology、Novartis

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[神経膠腫治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆